Unfolding the Mutational Landscape of Human Melanoma  by Davar, Diwakar et al.
tion from ME2 downregulation obser-
ved by Chang et al. (2014) could be
responsible for the AMPK activation.
Previously, the activity of AMPK in
melanoma was found to be repressed
by BRAF V600E mutant, a major driver
of melanoma (Zheng et al., 2009).
It would be interesting to determine
whether BRAF and ME2 coordinate in
attenuating AMPK activity in melanoma.
In addition, whether AMPK is indeed
a critical mediator of ME2’s effects on
cell proliferation and tumor growth in
melanoma needs to be addressed
experimentally.
The critical role of AMPK in suppres-
sing cell growth and proliferation raises
the interesting possibility that activation
of this pathway would suppress tumor
growth. More recently, phenformin, an
inhibitor of the mitochondria complex I
respiratory chain and an AMPK activa-
tor, was shown to enhance the anti-
tumor activitiy of BRAF inhibitors
in cultured melanoma cells and to
promote tumor regression in several
xenograft models and a genetically engi-
neered BRAF V600E–driven mouse
model of melanoma (Yuan et al.,
2013). Phenformin selectively targets a
minor subpopulation (approximately
5–10%) of melanoma cells expressing
JARID1B, a H3K4 demethylase and
marker for slow cycling cells, but
it has lower anti-tumor activity on the
JARID1B-negative cells (Yuan et al.,
2013). Conversely, although BRAF
inhibitors are effective in killing the
bulk of BRAF mutant melanoma
tumors––i.e., JARID1B-negative cells––
they do not appear to be effective
on JARID1B-positive cells (Yuan et al.,
2013). These results suggest that meta-
bolic heterogeneity exists in these
tumors, and this may contribute to
different states of treatment sensitivity
and resistance. The metabolic differen-
ces between these two subpopulations
of cells are still uncharacterized. It
certainly would be interesting to
investigate whether ME2 contributes to
this metabolic heterogeneity.
In summary, the work by Chang et al.
(2014) characterizes the function
of ME2 in melanoma, providing new
insight into metabolic reprograming
in melanoma. These findings suggest
a previously unknown vulnerability of
melanoma cells. If the catalytic activity
of ME2, indeed, proves to be critical
for the biological roles characterized in
this study, small molecule inhibitors of
ME2 might be exploited for melanoma
therapy.
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Unfolding the Mutational Landscape of
Human Melanoma
Diwakar Davar1, Yan Lin2 and John M. Kirkwood1
Over the preceding two decades, sophisticated sequencing techniques have
been used to characterize the genetic drivers of adult melanoma. However,
our understanding of pediatric melanomas is still rudimentary. In this report,
we comment on a thorough multi-platform analysis of common pediatric
melanoma subsets, including pediatric conventional melanoma (CM), congenital
nevus-derived melanoma (CNM), and Spitzoid melanoma (SM), contributed
by Lu et al.
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Data from whole-genome and -exome
sequencing (WGS/WES) and The Cancer
Genome Atlas (TCGA) have revealed
multiple new insights to the nature of
cutaneous melanoma, etiology, and
potential avenues of therapy. First, the
role of oral BRAF/MEK inhibitors (based
upon the frequency of B50% with UV
signature activating mutations in BRAF
and the MAPK pathway) has become
abundantly apparent. Further, the muta-
tional landscape and high frequency of
mutations observed in cutaneous mela-
noma, which exceeds those of all other
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solid tumors, have also provided sup-
port for our pursuit of immunotherapies
that historically have been singularly
successful in treating melanoma. The
prospects for the therapy of melanoma,
with two BRAF inhibitors, one MEK
inhibitor, and the first combination of
these agents, as well as five immuno-
therapies approved to date, have
expanded remarkably in the past several
years. A neglected but important aspect
of the problem of melanoma is with
respect to the patients who develop this
disease at or before puberty. These
pediatric and young adult (PAYA) mel-
anomas have been studied clinically
and demographically, but until recently
they have not been characterized
with respect to the fundamental drivers
of melanoma (Averbook et al., 2013;
McCormack et al., 2014). The para-
doxes of the childhood melanomas
are many—beginning with the entity of
spindle cell or spitzoid lesions, which
are often difficult to define pathologi-
cally or clinically, and the fraction of
melanomas that are derived from con-
genital garment–type nevi, which have
been the focus of much attention but
few rigorous studies. However, what has
been termed ‘‘conventional melanoma’’
in the PAYA population is clinically
indistinguishable from the adult coun-
terpart of the disease, and it remains
the largest fraction. Here, the role of UV
mutagenesis might have been presumed
to be less than that for adults––given the
shorter potential for UV exposure.
Further, the role and meaning of lym-
phatic traffic have been of interest, given
the regular pursuit of sentinel node
biopsy in lesions over stage IA among
adults. However, the role and meaning
of lymphatic pathways of dissemination
have been confounded by the paradox
that the melanomas of the young are
more likely to be detected in regional
nodal basins thickness-for-thickness
than among older patients (Sondak
et al., 2004)—hence, the question of
the biological consequences of nodal
disease detected in the pediatric and
adolescent/young adult populations
remains unanswered.
Our understanding of genomic drivers
in melanoma has paralleled the increas-
ing sophistication of sequencing techni-
ques over the last two decades. Early
studies utilized pyrosequencing, a mod-
ification of the Sanger ‘‘chain termina-
tion’’ method, and mapped melanoma
susceptibility loci to individual chromo-
somal alterations on chromosomes 9p
and 10q—since determined to be the
loci of tumor suppressor genes CDKN2A
and PTEN, respectively (Herbst et al.,
1994; Kamb et al., 1994; Guldberg
et al., 1997). First generation studies
relied on hotspot sequencing and
required some knowledge of where
mutations were located; these were
consequently limited in bandwidth and
throughput. Development of less
expensive high-throughput sequen-
cing technologies spurred interest in
genome-wide techniques such as
comparative genomic hybridization,
permitting detection of DNA copy
number variants (CNV) on formalin-
fixed paraffin-embedded (FFPE) tissues.
Various CNVs, including loss of 9p/10q,
focal loss of 6q/8p, and gains/ampli-
fications of 1q/2/4q/6p/7/8/11q/17/20,
were frequently found in melanoma but
absent in benign nevi (Bastian et al.,
1998). Classification of melanomas was
advanced significantly by Curtin et al.
(2005) who accurately subclassified
cutaneous melanomas on the basis of
the number of chromosomal aberrations,
and BRAF/NRAS mutational status, into
cutaneous melanomas with associated
chronic sun damage (CSD), those with-
out CSD, and mucosal and acral mela-
nomas (also without solar damage).
Subsequently, Bastian and colleagues
established that mutations and/or copy
number increases in KIT and GNAQ11/
GNAS were important drivers of muco-
sal and uveal melanoma respectively
(Curtin et al., 2006; Van Raamsdonk
et al., 2009). These findings have
directly parsed with the development of
inhibitors targeting the mitogen-activated
protein kinase (MAPK) pathway and the
regulatory approval of BRAF inhibitors
vemurafenib (Zelboraf, Genentech) and
dabrafenib (Tafinlar, GlaxoSmithKline)
and MEK inhibitor trametinib (Mekinist,
GlaxoSmithKline) as well as the combi-
nation of dabrafenib and trametinib for
treatment of BRAF mutant melanoma.
Identification of oncogenic drivers
in adult cutaneous melanoma has been
complicated by the unprecedented high
baseline frequency of somatic mutations
in melanoma tumor tissue (B14 muta-
tions per megabase). This rate is higher
compared with that of any other solid
tumor and partially reflective of the etio-
logic role of UV radiation expo-
sure (Lawrence et al., 2013). Hence,
approaches that rely on statistical
methods to distinguish mutational hot-
spots from mutationally quiescent areas
are unable to reliably distinguish driver
from passenger mutations in this disease.
Exposure to UV radiation is associated
with single base mutations (typically
cytidine to thymidine (C-T) substi-
tutions in pyrimidines), which constitute
a ‘‘UV radiation–induced mutational sig-
nature’’ (Pfeifer et al., 2005; Greenman
et al., 2007). More recently, high-through-
put approaches with next-generation
sequencing (NGS) have been utilized to
analyze WGS/WES, while compensating
for elevated baseline mutation frequencies
and the prevalence of UV mutational
signatures, and have identified novel
genes, including ARID2, PPP6C, RAC1,
SNX31, STK19, and TACC1 in melanoma
tumorigenesis (Hodis et al., 2012;
Krauthammer et al., 2012). These genes
Clinical Implications
 Pediatric CM and adult melanoma are both associated with high rates of
somatic mutations and activating BRAF/TERT-p mutations.
 CNM and SM are distinct entities: CNM is characterized by NRAS
mutations, a high somatic mutation burden, and a poor prognosis,
whereas SM is distinguished by novel kinase fusions, a low somatic
mutation load, and a relatively benign prognosis.
 Enrollment of pediatric CM patients in adult melanoma trials and tumor
banking of pediatric CNM/SM to further characterize the natural history
and etio-pathogenetic features should be a priority.
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are involved in canonical cellular
pathways such as RB, p53, and Aurora
kinase and their dysregulation suggest
new potential targets for rational drug
development.
Contrary to the situation in adult
melanoma, much less is known about
pediatric melanoma. Pediatric melano-
mas are rare—accounting for only 2%
of all malignancies in patients below
20 years of age, the majority of which
(75%) were seen to occur in patients
between 15 and 19 years in a 2006–
2010 SEER analysis (Howlader et al.,
2014). For reasons that likely include
increasing recreational sun exposure,
the incidence of pediatric melanoma
is rising, especially in the cohort of
patients aged 15–19. The actual inci-
dence may be higher because of the
inherent diagnostic challenges asso-
ciated with pigmented skin lesions in
pediatric patients. At least three distinct
melanocytic lesions have been identi-
fied in this age cohort, each with a
unique pattern of clinical behavior and
a distinct molecular profıle. Similar to
adult melanoma, pediatric patients with
distant metastatic disease have a high
mortality rate exceeding 80% (Lange
et al., 2007). A recent report of a coope-
rative group registry of melanomas
and atypical melanocytic lesions in
PAYA patients has shown that many of
the same prognostic features that have
been of use in prognosticating risk in
adult melanoma do apply, without
significant modification for the younger
population (Averbook et al., 2013).
It is against this background that
Lu et al. (2014) have characterized the
mutational landscape of what has been
designated ‘‘conventional melanoma’’
(CM), in relation to congenital nevus–
derived melanoma (CNM) and the
PAYA entity known as spitzoid mela-
noma (SM) in a cohort of 23
pediatric patients using several plat-
forms, including WGS/WES, the
molecular inversion probe assay,
and targeted sequencing (Lu et al.,
2014). The authors are to be
commended for conducting the
first large-scale well-annotated analysis
of pediatric patients using clinically
relevant tumor subtypes. In CM, the
authors noted a high somatic mutation
burden (14.36 mutations per megabase)
that mirrors adult melanoma, with a
high percentage (480%) of single base
mutations (typically C-T or A-G
transitions), most (490%) of which
occurred 3’ to pyrimidine base, a high
ratio of synonymous to silent
(1.27–2.22) mutations, and a lower
mutation frequency on the transcribed
compared with the untranscribed strand.
Most CM patients had mutations in BRAF
(11/13 patients) and TERT-p (12/15
patients), while approximately half had
PTEN copy number changes. Interes-
tingly, TERT-p and BRAF mutations
were not mutually exclusive. In CNM
and SM, BRAF mutations were not
commonly identified, although NRAS
mutations were identified in both CNM
patients. TERT-p mutations were
uncommon in both CNM and SM,
although the sole SM patient whose
disease spread hematogenously had a
TERT-p mutation. Two of the five SM
patients had novel kinase fusions
(NTRK1 and BRAF), whereas all three
CNM patients (and only these patients in
this series) had NRAS mutations.
Although enticing and thought
provoking, the low numbers of patients
in the CNM and SM samples—3 CNM
and 2 SM respectively—preclude signifi-
cant conclusions being drawn.
In summary, the authors of this paper
are to be commended for performing
the first large-scale, well-annotated
genetic and molecular analysis of pedia-
tric melanomas. It is self-evident that
pediatric CM and adult cutaneous mel-
anoma are essentially the same disease.
Similar to adult melanoma, pediatric
CM is associated with a high somatic
mutation load, high frequencies of acti-
vating BRAF mutations, and PTEN copy
number changes, with resulting acti-
vation of MAPK and PI3K/AKT cellular
signaling pathways. Given the poor
prognosis of these patients, pediatric
CM patients should be staged and follo-
wed in a manner similar to adult
patients. Promising trials of immuno-
therapy, targeted therapy, and/or
combinations hitherto restricted to adult
patients aged 18 and above should
consider enrolling PAYA patients with
advanced melanoma.
Pediatric CNM and SM are distinct
clinical entities. The high incidence of
NRAS mutations, high somatic mutation
burden, and grim prognosis in CNM
contrasts distinctly with the absence of
BRAF/NRAS mutations, low-somatic
mutation burden, and potentially more
benign prognosis of SM. Further study is
required to characterize the natural his-
tory of SM and specifically the prognos-
tic role of TERT-p mutations as markers
of the subset of these tumors that have
the capacity for distant metastasis.
The observation of novel kinase fusions
in SM is supported by earlier data
reported by Boris Bastian at ASCO
2013 (Stephens et al., 2013). The kinase
fusions observed (Lu et al., NTRK1/BRAF;
Stephens et al., NTRK1/BRAF/ROS1/ALK/
RET) are constitutively expressed and
result in active oncogenes that drive
malignant transformation. Should these
observations be corroborated, the
clinical implications will be tremendous
both in terms of diagnosis/prognosis and
in the management of advanced disease.
The unraveling of the mutational
landscape in adult melanoma in the last
decade is a standout success of the
genomic revolution in molecular bio-
logy and oncology—both in terms of
understanding a particularly thorny dis-
ease entity, and in terms of developing
actionable targets that have improved
patient survival. We appear to be on the
cusp of a similar revelation in pediatric
melanoma, with potentially even greater
diagnostic, prognostic, and therapeutic
implications associated with the longer
life horizons of pediatric patients. The
findings of Lu et al. (2014) should sound
a tocsin to galvanize prospective studies
and clinical trial enrolment of patients
with PAYA cutaneous melanoma, of the
three variants that have now been
distinguished: conventional, congenital
nevus-derived, and Spitzoid.
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Silencing Autocrine Death: A Ubiquitin
Ligase that Blocks Activation-Induced
Cell Death in Cutaneous T-Cell
Lymphoma
Claus-Detlev Klemke1, Maria Feoktistova2 and Martin Leverkus1,2
Cutaneous T-cell lymphoma (CTCL) tumor cells lack the ability of activated T cells
to undergo TCR/CD3-mediated activation-induced cell death (AICD). In this issue,
the study reported by Wu et al. demonstrates that c-CBL (Casitas B-lineage
Lymphoma proto-oncogene) is overexpressed in CTCL. When CTCL cells lose
c-CBL, AICD is enhanced. Furthermore, combination therapy with methotrexate
(a known demethylating agent for the CD95 gene) in combination with the loss of
c-CBL increases CTCL cell death. Therefore, inhibition of c-CBL could represent a
method of sensitizing lymphoma cells to enhance AICD. Armed with their novel
data, the investigators envision combination therapies that target c-CBL to
reactivate AICD in the malignant T cells whenever responsiveness to TCR/CD3
signaling is retained.
Journal of Investigative Dermatology (2015) 135, 662–665. doi:10.1038/jid.2014.468
Cutaneous T-cell lymphomas (CTCLs)
are a heterogeneous group of extranodal
non-Hodgkin lymphomas with an esti-
mated annual incidence of 1/100,000.
Mycosis fungoides (MF) and the Se´zary
syndrome (SS), characteristically the
most frequent forms of CTCL, are most
commonly treated by dermatooncolo-
gists (Klemke, 2014). One important
hallmark of cancer that is thought to
represent an obstacle to therapy of
CTCL is cell death resistance (Hanahan
and Weinberg, 2011). Most types of
CTCL run an indolent course over
years to decades, with skin lesions that
persist (patches and plaques). This
clinical observation suggests a
pathophysiological relevant defect in
apoptosis rather than increased
proliferation as important in disease
development. It has been known for a
long time that one characteristic of
CTCL cells relevant for tumor progres-
sion and overall prognosis is the deve-
lopment of resistance to CTCL cell–
intrinsic apoptosis. A signaling pathway
that holds promise to break acquired
cell death resistance in CTCL is the
death receptor (DR)-induced cell death
pathway, which is controlled, at least in
part, by CD95/CD95 ligand (CD95L), a
process coined as activation-induced
cell death (Krammer et al., 2007).
CD95-induced cell death is the proto-
typical example of extrinsic cell death,
which can also be induced by other
membrane-bound and soluble ligands
(death ligands; DL), such as tumor
necrosis factor–related apoptosis-indu-
cing ligand and tumor necrosis factor.
Stimulation of the DR results in initia-
tion of an intracellular signaling cas-
cade, and a critical step during this
process is the activation of pro-cas-
pase-8 within the death-inducing signal-
ing complex (DISC). The initiator,
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